

CLAIMS

- sub
A8
1. A composition that retards the transformation of a hormone-dependent cancer to a non-hormone-dependent cancer, which contains a hormonal agent.
 2. The composition as claimed in claim 1, wherein said hormonal agent is an LH-RH derivative.
 3. The composition as claimed in claim 2, wherein said LH-RH derivative is an LH-RH agonist.
 4. The composition as claimed in claim 3, wherein said LH-RH derivative is a peptide represented by the formula:
5-oxo-Pro-His-Trp-Ser-Tyr-Y-Leu-Arg-Pro-Z
wherein Y represents a residue selected from among DLeu, DAla, DTrp, DSer(tBu), D2Nal and DHis(ImBzl); Z represents NH-C₂H₅ or Gly-NH₂, or a salt thereof.
 5. The composition as claimed in claim 3, wherein said LH-RH derivative is 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH-C₂H₅ or an acetate thereof.
 6. The composition as claimed in claim 1, which contains in addition to a hormonal agent an agent that inhibits the action of a cell growth factor or a receptor thereof.
 7. The composition as claimed in claim 6, wherein said cell growth factor is ① EGF or a substance possessing substantially the same activity as it, ② insulin or a substance possessing substantially the same activity as it, or ③ FGF or a substance possessing substantially the same activity as it.
 8. The composition as claimed in claim 1, which is a preventive/therapeutic composition for prostatic cancer, ovarian cancer, cervical cancer or breast cancer.
 9. Use of a hormonal agent for retarding the transformation of a hormone-dependent cancer to a non-hormone-dependent cancer.

11. A method of retarding the transformation of a hormone-dependent cancer to a non-hormone-dependent cancer in a mammal carrying a hormone-dependent cancer, comprising administering a hormonal agent to said mammal.